SEC Form DEFA14A filed by Lyell Immunopharma Inc.
$LYEL
Biotechnology: Pharmaceutical Preparations
Health Care
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 14A
Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934
(Amendment No. )
|
Filed by the Registrant
|
☒ | |
|
|
Filed by a Party other than the Registrant
|
☐ | |
Check the appropriate box:
|
☐
|
| |
Preliminary Proxy Statement
|
|
☐
|
| |
Confidential, for Use of the Commission Only (as permitted by Rule
14a-6(e)(2))
|
|
☐
|
| |
Definitive Proxy Statement
|
|
☒
|
| |
Definitive Additional Materials
|
|
☐
|
| |
Soliciting Material Pursuant to § 240.14a-12
|
|
LYELL IMMUNOPHARMA, INC.
|
|
(Name of Registrant as Specified In Its Charter)
|
|
|
|
(Name of Person(s) Filing Proxy Statement if other than the Registrant)
|
Payment of Filing
Fee (Check all boxes that apply):
|
☒
|
| |
No fee required
|
|
☐
|
| |
Fee paid previously with preliminary materials
|
|
☐
|
| |
Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11
|
